Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 36 peer-reviewed journal articles Updated
Pulmonology · Pulmonary Mycobacterium avium Complex Disease

How Do Doctors Tell if Pulmonary MAC Treatment Is Working?

At a Glance

Doctors judge pulmonary MAC treatment mainly by repeated sputum cultures: culture conversion means at least three negative cultures collected at least four weeks apart. Symptoms, CT scans, and lung function tests add context but cannot alone prove MAC has cleared.

In this answer

4 sections

01

The Primary Measure: Sputum Culture Conversion

02

Tracking Your General Health and Function

03

Why Symptoms Might Persist

04

The Role of Imaging and Lung Function Tests

Key Takeaways

  • The best sign that pulmonary MAC treatment is working is repeated negative sputum cultures.
  • Symptom improvements—like having more energy or coughing less—are important for your quality of life, but they do not prove the bacteria are clearing [1][2][3].
  • Cough and fatigue often improve slowly or persist due to permanent airway changes or medication side effects [4][5].
  • Never assume persistent symptoms mean the treatment has failed, and never stop taking your medications without consulting your doctor.

Doctors determine if your treatment is working primarily by testing your sputum (phlegm) at regular intervals. A “culture” is a lab test that checks if MAC bacteria will grow from your sample. The main goal of treatment is sputum culture conversion.

The Primary Measure: Sputum Culture Conversion

A single negative test is not enough to prove the treatment is working because a negative culture only means MAC did not grow in that specific sample [6]. It does not guarantee that your lungs are entirely cleared of the bacteria. Doctors define culture conversion as having at least three consecutive negative sputum cultures, collected at least four weeks apart [4][7][6].

The date of your first negative culture in that series is considered your “conversion date.” If you have trouble producing sputum, your doctor may suggest techniques to induce sputum or, in some cases, use specialized procedures to obtain a sample.

The Treatment Timeline

Achieving conversion does not mean you stop treatment. Standard medical guidelines recommend continuing your antibiotic therapy for at least 12 full months after your conversion date [8][9][6]. This extended treatment reduces the risk of the disease returning. Even after successful treatment, recurrences can happen, either from the original bacteria (relapse) or a new infection (reinfection) [10][11].

What if Cultures Remain Positive?

If your cultures remain positive after six months of guideline-based treatment, this is often referred to as “refractory” disease. This does not mean you should stop your medications. Instead, it warrants a thorough review by an NTM-experienced specialist. They will check your medication adherence, look for drug interactions, test the bacteria for drug resistance (susceptibility testing), and consider adjusting your regimen or adding specialized medications like inhaled liposomal amikacin [12][13][14].

Tracking Your General Health and Function

While sputum cultures measure the bacteria, other tests help doctors monitor your overall physical function. However, these are supportive measures and can be influenced by many other health factors:

  • Weight and Nutrition: Unexplained weight loss is an important symptom to report, while stabilizing your weight and maintaining good nutrition reflect better overall health [15][16]. However, your body weight alone does not reliably show that MAC has cleared.
  • Activity Tolerance: Your doctor may use a 6-minute walk test to see how far you can walk and measure your exertion. While useful for tracking your functional stamina, improvements in walk distance do not directly prove MAC clearance, as fatigue and exercise tolerance are also affected by heart health, anemia, or muscle conditioning [17][18][19].

Why Symptoms Might Persist

It is common and understandable to feel frustrated if your cultures are negative but you still have a chronic cough or feel exhausted [4][20]. Symptoms can persist for several reasons:

Coexisting Bronchiectasis

Many people with pulmonary MAC also have bronchiectasis, a condition where the lung’s airways are widened, scarred, and inflamed [21][22][23]. MAC medications treat the bacteria but do not reverse this structural airway damage. Because the damaged airways continue to collect mucus, you may continue to experience a daily cough. Many patients find relief through an individualized airway-clearance plan, which may include chest physiotherapy or nebulized saline.

Medication Side Effects

MAC treatment involves powerful antibiotics that can cause side effects mimicking disease symptoms:

  • Inhaled Amikacin: Usually prescribed for refractory disease, this medication commonly causes hoarseness (dysphonia), throat irritation, and persistent cough [24][4][25].
  • Ethambutol: Can cause visual changes, including blurry vision or difficulty seeing colors, requiring regular monitoring [24][26].
  • Intravenous Amikacin or Aminoglycosides: Require monitoring for hearing loss, balance issues, and kidney toxicity [27][28][25].
  • Macrolides and Rifamycins: These can interact with other drugs and require monitoring for liver function and heart rhythm [26][29][30].

Important Safety Warning: When to Seek Immediate Care
Do not assume that all worsening symptoms are just normal side effects or part of recovery. Contact your healthcare team promptly or seek urgent care if you experience:

  • Worsening or severe shortness of breath
  • Coughing up significant amounts of blood
  • High fever or chest pain
  • New vision changes, hearing loss, ringing in the ears, or balance problems
  • Jaundice (yellowing of the skin or eyes) or dark urine
  • Severe rash or severe vomiting

The Role of Imaging and Lung Function Tests

To get a complete picture of your health, doctors may selectively order structural and functional tests. These are not routine replacements for sputum cultures, but they provide important context:

  • High-Resolution CT (HRCT) Scans: These detailed scans show physical damage in your lungs, such as cavities or bronchiectasis [31]. While HRCT helps monitor structural changes, CT scans do not perfectly match sputum results. Some structural changes may remain abnormal permanently, even when the bacteria are gone [32][33].
  • Pulmonary Function Tests (PFTs): These breathing tests measure airflow, lung volumes, and gas transfer [34][35][36]. They help track how much your overall lung capacity is restricted or obstructed by conditions like bronchiectasis, but they do not measure the presence of bacteria.

Common questions in this guide

What is the clearest sign that pulmonary MAC treatment is working?
The clearest sign is repeated negative sputum cultures, meaning MAC does not grow from collected phlegm samples. Doctors generally define culture conversion as at least three consecutive negative cultures collected at least four weeks apart; symptoms alone cannot confirm that the bacteria are clearing.
How long do I need treatment after my sputum cultures turn negative?
Treatment usually continues for at least 12 full months after the conversion date, which is the date of the first negative culture in a qualifying series. Do not stop antibiotics when one culture is negative unless your treating clinician tells you to.
What does it mean if my MAC cultures are still positive after six months?
Positive cultures after six months of guideline-based treatment may be called refractory pulmonary MAC disease. This calls for review by an NTM-experienced specialist, including checking adherence, drug interactions, and antibiotic susceptibility; do not stop treatment on your own.
Why do I still cough or feel tired if my MAC cultures are negative?
A cough or fatigue can persist because bronchiectasis leaves the airways widened, scarred, and prone to collecting mucus, and some MAC medicines can also cause cough, hoarseness, or other symptoms. Persistent symptoms do not necessarily mean treatment has failed, so discuss them with your clinician.
Do CT scans or breathing tests show whether MAC has cleared?
High-resolution CT scans and pulmonary function tests help doctors track structural lung damage and breathing capacity, but they do not directly show whether MAC bacteria are present. Abnormal CT findings or reduced lung function may remain even after cultures become negative.
When should I call my doctor about symptoms during MAC treatment?
Contact your healthcare team promptly for worsening shortness of breath, significant coughing up of blood, high fever, chest pain, new vision or hearing changes, ringing in the ears, balance problems, jaundice, dark urine, severe rash, or severe vomiting. These symptoms may signal a serious illness or medication reaction and should not be dismissed as normal recovery.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I producing sputum frequently enough for serial cultures, and if not, should we consider techniques to induce sputum?
  2. 2.How many consecutive negative sputum cultures have I had so far, and what is our target date for completing the 12-month post-conversion phase?
  3. 3.Are my persistent symptoms likely due to underlying bronchiectasis or a medication side effect, and is there an airway-clearance technique that might help?
  4. 4.What specific toxicity monitoring do I need for my current medication regimen, such as liver, kidney, vision, or hearing checks?
  5. 5.If my cultures are still positive after six months, how will we reassess my treatment plan, adherence, and drug susceptibility?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can Pulmonary MAC Cause Lasting Lung Damage or Shorten Life?Can Gardening Expose You to Mycobacterium avium Complex?Can You Have Pulmonary MAC With a Negative AFB Smear?Does an AFB-Positive Sputum Test Mean I Have Tuberculosis?Does a Positive MAC Sputum Culture Always Mean Lung Disease?Why Isn't Pulmonary MAC Contagious to Your Family?How Often Are CT Scans and Breathing Tests Used for MAC?How Quickly Does Untreated Pulmonary MAC Disease Progress?How Should I Collect Sputum for Pulmonary MAC Diagnosis?Is MAC After Culture Conversion a Relapse or Reinfection?Should I Get Immune or Lung Testing for Pulmonary MAC?What Do CT Scan Findings Mean in Pulmonary MAC Disease?What Factors Affect Your Chances of Clearing Pulmonary MAC?What Follow-Up Is Needed After Pulmonary MAC Treatment?What Tests Check for Disseminated MAC Outside the Lungs?What Tests Diagnose Pulmonary MAC If I Can't Produce Sputum?What Water Precautions Are Recommended for MAC Lung Disease?When Is Watchful Waiting Appropriate for Pulmonary MAC?Why Do MAC Species ID and Macrolide Testing Matter?

References

References (36)
  1. 1

    Relationship between culture conversion and clinical outcomes in nontuberculous mycobacterial pulmonary disease: Narrative review.

    Winthrop KL, Mingora CM, Varley CD, et al.

    Respiratory medicine 2025; (241()):108052 doi:10.1016/j.rmed.2025.108052.

    PMID: 40132751
  2. 2

    Development of Drugs for Nontuberculous Mycobacterial Disease: Clinicians' Interpretation of a US Food and Drug Administration Workshop.

    Flume PA, Griffith DE, Chalmers JD, et al.

    Chest 2021; (159(2)):537-543 doi:10.1016/j.chest.2020.08.2055.

    PMID: 32853648
  3. 3

    Patient-Reported Symptom and Health-Related Quality-of-Life Validation and Responsiveness During the First 6 Months of Treatment for Mycobacterium avium Complex Pulmonary Disease.

    Henkle E, Quittner AL, Dieckmann NF, et al.

    Chest 2023; (164(1)):53-64 doi:10.1016/j.chest.2023.02.015.

    PMID: 36803647
  4. 4

    Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study.

    Griffith DE, Eagle G, Thomson R, et al.

    American journal of respiratory and critical care medicine 2018; (198(12)):1559-1569 doi:10.1164/rccm.201807-1318OC.

    PMID: 30216086
  5. 5

    Beyond Symptoms: Radiologic identification of asymptomatic Mycobacterium avium complex pulmonary infections.

    Fujiwara K, Watanabe F, Uesugi F, et al.

    Respiratory medicine 2024; (226()):107627 doi:10.1016/j.rmed.2024.107627.

    PMID: 38604553
  6. 6

    Microbiological Cure at Treatment Completion Is Associated With Longer Survival in Patients With Mycobacterium avium Complex Pulmonary Disease.

    Kim JY, Park J, Choi Y, et al.

    Chest 2023; (164(5)):1108-1114 doi:10.1016/j.chest.2023.06.015.

    PMID: 37423256
  7. 7

    Clinical characteristics and early outcomes of patients newly diagnosed with pulmonary Mycobacterium avium complex disease.

    Hagiwara E, Katano T, Isomoto K, et al.

    Respiratory investigation 2019; (57(1)):54-59 doi:10.1016/j.resinv.2018.08.006.

    PMID: 30366835
  8. 8

    Mycobacterium avium Complex: Addressing Gaps in Diagnosis and Management.

    Daley CL, Winthrop KL

    The Journal of infectious diseases 2020; (222(Suppl 4)):S199-S211 doi:10.1093/infdis/jiaa354.

    PMID: 32814943
  9. 9

    Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure.

    Griffith DE, Thomson R, Flume PA, et al.

    Chest 2021; (160(3)):831-842 doi:10.1016/j.chest.2021.03.070.

    PMID: 33887244
  10. 10

    Understanding recurrence in Mycobacterium avium complex pulmonary disease: genotypic strategies to support clinical decision-making.

    Trinh MP, Shin SJ, Shin M-K

    Journal of clinical microbiology 2026; (64(3)):e0108625 doi:10.1128/jcm.01086-25.

    PMID: 41190925
  11. 11

    Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease.

    Jhun BW, Moon SM, Kim SY, et al.

    Antimicrobial agents and chemotherapy 2018; (62(2)) doi:10.1128/AAC.01812-17.

    PMID: 29203483
  12. 12

    Amikacin Liposomal Inhalation Suspension: Advances in Application Against Refractory Mycobacterium avium Complex.

    Li X, Li D, Guo S, Li Y

    Infection and drug resistance 2026; (19()):627337 doi:10.2147/IDR.S627337.

    PMID: 42667005
  13. 13

    Clinical Implications of Time to Culture Conversion in Mycobacterium Avium Complex Pulmonary Disease.

    Kwak N, Cho Y, Bae J, et al.

    Open forum infectious diseases 2025; (12(11)):ofaf664 doi:10.1093/ofid/ofaf664.

    PMID: 41234300
  14. 14

    The Association Between Sputum Culture Conversion and Mortality in Cavitary Mycobacterium avium Complex Pulmonary Disease.

    Lee JK, Kim S, Chong YP, et al.

    Chest 2024; (166(3)):442-451 doi:10.1016/j.chest.2024.03.027.

    PMID: 38508335
  15. 15

    BACES score: a predictor of health-related quality of life and associated factors in patients with nontuberculous mycobacterial pulmonary disease.

    Park Y, Kwak N, Hwang H, et al.

    Scientific reports 2025; (15(1)):26257 doi:10.1038/s41598-025-09971-3.

    PMID: 40683901
  16. 16

    Association between nutritional status and clinical characteristics in nontuberculous mycobacterial pulmonary disease: preliminary results from the NTM-KOREA cohort.

    Yang S, Park Y, Kwak N, et al.

    Respiratory research 2026; (27(1)).

    PMID: 41723437
  17. 17

    Association between six-minute walk test parameters and the health-related quality of life in patients with pulmonary Mycobacterium avium complex disease.

    Yagi K, Asakura T, Namkoong H, et al.

    BMC pulmonary medicine 2018; (18(1)):114 doi:10.1186/s12890-018-0686-5.

    PMID: 30005658
  18. 18

    Longitudinal significance of six-minute walk test in patients with nontuberculous mycobacterial pulmonary disease: an observational study.

    Morita A, Yagi K, Asakura T, et al.

    BMC pulmonary medicine 2023; (23(1)):247 doi:10.1186/s12890-023-02528-y.

    PMID: 37415094
  19. 19

    Clinical significance and safety of combined treatment with chemotherapy and pulmonary rehabilitation regarding health-related quality of life and physical function in nontuberculous mycobacterial pulmonary disease.

    Omatsu S, Tabusadani M, Yamane K, et al.

    Respiratory investigation 2022; (60(5)):674-683 doi:10.1016/j.resinv.2022.06.006.

    PMID: 35843830
  20. 20

    Relapse versus Reinfection of Mycobacterium avium Complex Pulmonary Disease. Patient Characteristics and Macrolide Susceptibility.

    Boyle DP, Zembower TR, Qi C

    Annals of the American Thoracic Society 2016; (13(11)):1956-1961 doi:10.1513/AnnalsATS.201605-344BC.

    PMID: 27599038
  21. 21

    Long-term clinical course of Mycobacterium avium complex pulmonary disease patients with treatment failure.

    Zo S, Choe J, Kim DH, et al.

    Antimicrobial agents and chemotherapy 2024; (68(12)):e0105524 doi:10.1128/aac.01055-24.

    PMID: 39470199
  22. 22

    Retrospective study of the predictors of mortality and radiographic deterioration in 782 patients with nodular/bronchiectatic Mycobacterium avium complex lung disease.

    Gochi M, Takayanagi N, Kanauchi T, et al.

    BMJ open 2015; (5(8)):e008058 doi:10.1136/bmjopen-2015-008058.

    PMID: 26246077
  23. 23

    Non-Cystic Fibrosis Bronchiectasis in Adults: A Review.

    Barker AF, Karamooz E

    JAMA 2025; (334(3)):253-264 doi:10.1001/jama.2025.2680.

    PMID: 40293759
  24. 24

    Lower dose of ethambutol may reduce ocular toxicity without radiological deterioration for Mycobacterium avium complex pulmonary disease.

    Ando T, Kage H, Matsumoto Y, et al.

    Respiratory investigation 2021; (59(6)):777-782 doi:10.1016/j.resinv.2021.06.010.

    PMID: 34389250
  25. 25

    Laryngitis after inhalation of liposomal amikacin.

    Morita A, Namkoong H, Hosoya M, Hasegawa N

    Clinical case reports 2022; (10(2)):e05350 doi:10.1002/ccr3.5350.

    PMID: 35369384
  26. 26

    Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

    Daley CL, Iaccarino JM, Lange C, et al.

    The European respiratory journal 2020; (56(1)) doi:10.1183/13993003.00535-2020.

    PMID: 32636299
  27. 27

    The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases.

    Yagi K, Ishii M, Namkoong H, et al.

    BMC infectious diseases 2017; (17(1)):558 doi:10.1186/s12879-017-2665-5.

    PMID: 28793869
  28. 28

    Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use.

    Hoy SM

    Clinical drug investigation 2021; (41(4)):405-412 doi:10.1007/s40261-021-01010-z.

    PMID: 33723805
  29. 29

    Serum concentrations of clarithromycin and rifampicin in pulmonary Mycobacterium avium complex disease: long-term changes due to drug interactions and their association with clinical outcomes.

    Shimomura H, Andachi S, Aono T, et al.

    Journal of pharmaceutical health care and sciences 2015; (1()):32 doi:10.1186/s40780-015-0029-0.

    PMID: 26819743
  30. 30

    Treatment for Mycobacterium avium complex lung disease.

    Pan SW, Shu CC, Feng JY, Su WJ

    Journal of the Formosan Medical Association = Taiwan yi zhi 2020; (119 Suppl 1()):S67-S75 doi:10.1016/j.jfma.2020.05.006.

    PMID: 32446754
  31. 31

    Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation.

    Urabe N, Sakamoto S, Tokita N, et al.

    BMC pulmonary medicine 2024; (24(1)):442 doi:10.1186/s12890-024-03261-w.

    PMID: 39256717
  32. 32

    Impact of chronic co-infection in pulmonary Mycobacterium avium complex disease after treatment initiation.

    Urabe N, Sakamoto S, Shimanuki Y, et al.

    BMC pulmonary medicine 2022; (22(1)):157 doi:10.1186/s12890-022-01947-7.

    PMID: 35468795
  33. 33

    Predictive risk factors of treatment-refractory Mycobacterium avium complex lung disease: a single-center retrospective cohort study.

    Saito T, Aono Y, Kono M, et al.

    Therapeutic advances in infectious disease 2025; (12()):20499361251331676 doi:10.1177/20499361251331676.

    PMID: 40292088
  34. 34

    Impact of cavity and infiltration on pulmonary function and health-related quality of life in pulmonary Mycobacterium avium complex disease: A 3-dimensional computed tomographic analysis.

    Asakura T, Yamada Y, Namkoong H, et al.

    Respiratory medicine 2017; (126()):9-16 doi:10.1016/j.rmed.2017.03.010.

    PMID: 28427555
  35. 35

    Longitudinal validity and prognostic significance of the St George's Respiratory Questionnaire in Mycobacterium avium complex pulmonary disease.

    Ogawa T, Asakura T, Suzuki S, et al.

    Respiratory medicine 2021; (185()):106515 doi:10.1016/j.rmed.2021.106515.

    PMID: 34175804
  36. 36

    Quantitative assessment of erector spinae muscles in patients with Mycobacterium avium complex lung disease.

    Asakura T, Yamada Y, Suzuki S, et al.

    Respiratory medicine 2018; (145()):66-72 doi:10.1016/j.rmed.2018.10.023.

    PMID: 30509718

This page is for informational purposes only and does not constitute medical advice. Your pulmonary or infectious-disease clinician should interpret your cultures, symptoms, scans, and medication effects before any treatment changes.

Get notified when new evidence is published on Mycobacterium avium complex disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.